Sclerosis in Medical Technology

Clay Walker's Band Against MS Foundation Donates $150,000 To Support Multiple Sclerosis Research

NASHVILLE, Tenn., July 6 /PRNewswire/ -- A Pebble Beach golf tournament pays off big for researchers looking for a cure for multiple sclerosis. The researchers took home the top prize: a $150,000 contribution from multi-platinum recording artist Clay Walker and the non-profit Band Against MS (BA...

Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line

Only 39 Percent of Newly Diagnosed Patients Receive a Drug Within One Year of Their First Diagnosis, According to a New Report from Decision Resources WALTHAM, Mass., April 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceut...

Ambrx and Merck Serono Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance

SAN DIEGO, Feb. 24 /PRNewswire/ -- Ambrx Inc, and Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced a global strategic collaboration to develop and commercialize Ambrx's ARX424 preclinical product candidate for the treatment of multiple sclerosis. ARX424 was created by A...

Diplomat Specialty Pharmacy Tapped by Teva Neuroscience for Therapy Optimization Study for Multiple Sclerosis (TOP MS)

SWARTZ CREEK, Mich., Oct. 10 /PRNewswire/ -- Diplomat Specialty Pharmacy announced today that Teva Neuroscience has selected Diplomat Specialty Pharmacy to be one of only three sites to participate in a large scale, national Therapy Optimization Study for Multiple Sclerosis (TOP MS). The goa...

Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)

SB-509 to be Evaluated in Repeat-Dosing Study in Subjects with ALS RICHMOND, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced today that it has opened a Phase 2 clinical trial (SB-509-801) to evaluate its drug, SB-509, in subjects with ALS, a pr...

Peptimmune Initiates Phase Ib Study of PI-2301 in Multiple Sclerosis Patients and Presentation at BIO 2008

CAMBRIDGE, Mass., June 17 /PRNewswire/ -- Peptimmune, Inc. a privately held biotechnology company, announced that physicians have treated the first participant in a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary...

Avicena Announces Positive Phase II Data for a Combination Trial Involving AL-08 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Selected Therapy Can Advance to Phase III Clinical Trial PALO ALTO, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Avicena Group, Inc. (OTC Bulletin Board: AVGO), a late-stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases, today announ...

Survival Data for Avicena's Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND

PALO ALTO, Calif., Oct. 18 /PRNewswire-FirstCall/ -- Avicena Group, Inc. (OTC Bulletin Board: AVGO), a late-stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases, announced today that data related to the Company's Amyotrophic Lateral Scler...

Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial in Secondary Progressive Multiple Sclerosis

INDIANAPOLIS and EDMONTON, Alberta, July 27 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY ) and BioMS Medical Corp. (TSX: MS) today announced that dirucotide did not meet the primary endpoint of delaying disease progression, as measured by the Expanded Disability Status Scale (...

AIMSPRO is Awarded TGA Orphan Status for the Treatment of Amyotrophic Lateral Sclerosis

LONDON, June 1 /PRNewswire/ -- Privately owned UK biotech company Daval International Limited ( http://www.davalinternational.com ) has been informed by Australia's Therapeutic Goods Administration (TGA) that its innovative anti-inflammatory agent AIMSPRO(R) has been awarded Orphan Status for ...

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis

- Primary Endpoint met With a Significant Reduction in Relapse Rate - Secondary Endpoints met Including MRI Measures, Proportion of Patients Relapse-Free and Disability Progression - Submission for Registration of Cladribine Tablets Planned for mid-2009 SEATTLE and GENEVA, April 30 ...

Young Smokers Increase Risk for Multiple Sclerosis

SEATTLE, Feb. 23 /PRNewswire-USNewswire/ -- People who start smoking before age 17 may increase their risk for developing multiple sclerosis (MS), according to a study released today that will be presented at the American Academy of Neurology's 61st Annual Meeting in Seattle, April 25 to May...

ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis

- Conference call webcast Monday, 5:00 p.m. EDT and Tuesday, 7:00 a.m. Australian EST at http://www.antisense.com.au and http://www.isispharm.com MELBOURNE, Australia and CARLSBAD, Calif., Sept. 22 /PRNewswire-FirstCall/ -- Antisense Therapeutics Ltd. (ASX: ANP) and Isis Pharmaceuticals,...

Merck Serono Announces Initiation of the ORACLE MS Trial to Evaluate Cladribine Tablets in Patients at Risk of Developing Multiple Sclerosis

- ORACLE MS Phase III Trial Will Assess Effectiveness of Cladribine Tablets in Preventing Conversion to Definite Multiple Sclerosis in Addition to the Fully Enrolled Phase III Pivotal Trial - - the CLARITY Study - - for Treatment of Relapsing Forms of...

Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis

GENEVA, Sept. 17 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that patient enrollment has been completed in the REFLEX trial (Rebif FLEXible dosing in early multiple sclerosis). This randomized, double-blind, placebo-controlled, international Phas...

Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis

CAMBRIDGE, Mass., July 30 /PRNewswire/ -- Peptimmune, Inc. a privately held biotechnology company, announced today the grant of US Patent Number 7,381,790 (the '790 patent) which protects the composition of matter for its PI-2301 peptide copolymer for the treatment of autoimmune diseases. PI...

Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis

CAMBRIDGE, Mass., March 18 /PRNewswire/ -- Peptimmune, Inc. a privately held biotechnology company, announced that it has completed its first clinical trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PI-2301, a novel peptide copolymer for the treatment of mu...

Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis

Preclinical profile and potential for lower cardiac toxicity drives investigator interest SEATTLE, March 6 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that its investigational drug pixantrone will be studied in a mult...

Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis

Company Received $5.2 Million in Cost Recovery from EAP in 2007 RICHMOND, Va., Jan. 24 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, today provided an update on the IPLEX(TM) Expanded Access Program (EAP) in Italy for the t...

Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis

Three-Year Analysis Demonstrates Robust, Highly Statistically Significant Treatment Effect of Alemtuzumab Compared to Rebif(R) CAMBRIDGE, Mass., Oct. 15 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ ) today announced that top-line, three-year data from a completed Phase ...

Peptimmune Initiates Phase I Study With a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis

CAMBRIDGE, Mass., Oct. 3 /PRNewswire/ -- Peptimmune, Inc. a privately held biotechnology company, announced that physicians have treated the first participant in a clinical trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PI-2301, a novel peptide copolymer f...

Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis

CAMBRIDGE, Mass., and BERLIN, Sept. 26 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ ) and Bayer Schering Pharma AG, Germany today announced that the first patient has been treated in the first of two planned Phase 3 trials examining the safety and efficacy of alemtuzumab for th...

MediciNova Announces Positive Clinical Results From MN-166 Phase II Multiple Sclerosis Trial

Conference Call to Discuss Results On Thursday, March 29, 2007, At 2:00 p.m. Pacific Time SAN DIEGO, March 27, 2007 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities ...

First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone Was More Cost-Effective Than Interferon Beta Therapies for Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

KANSAS CITY, Mo.--(BUSINESS WIRE)--Apr 11, 2007 - A comparison of the long-term economic outcomes of four immunomodulatory drug therapies combined with symptom management versus symptom management alone revealed that COPAXONE(R) (glatiramer acetate injection) was the most cost-effective treatment s...

Data Published in Neurology Showed That Higher Dose of Copaxone Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS)

JERUSALEM--(BUSINESS WIRE)--Apr 17, 2007 - A 9-month, randomized, double-blind, parallel-group Phase II study of 90 patients comparing a 40 mg dose of COPAXONE(R) given daily to the currently approved COPAXONE(R) 20 mg dose showed a 38 percent greater reduction in inflammatory disease activity as m...

Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN

Interim analysis of Phase 2 comparative study showed significant results in favor of alemtuzumab versus Rebif CAMBRIDGE, Mass. and WAYNE, N.J., May 02, 2007 /PRNewswire-FirstCall/ -- Genzyme Corporation and Bayer HealthCare Pharmaceutical today announced detailed interim results from the CAMMS223 ...

Acorda Therapeutics Presents Data from its Phase 3 Study of Fampridine-SR in Multiple Sclerosis at the American Academy of Neurology Meeting

BOSTON--(BUSINESS WIRE)--May 2, 2007 - Acorda Therapeutics, Inc.(R) (Nasdaq: ACOR) today presented data from a Phase 3 clinical trial of Fampridine-SR in people with multiple sclerosis (MS) at the American Academy of Neurology meeting. Andrew Goodman, M.D., Director of the Multiple Sclerosis Center...

Copaxone Treatment over Two Years after Short Term Induction with Mitoxantrone Provided Sustained Benefits to Active Relapsing-Remitting Multiple Sclerosis Patients

KANSAS CITY, Mo.--(BUSINESS WIRE)--May 4, 2007 - New data have demonstrated that relapsing-remitting multiple sclerosis (RRMS) patients treated with COPAXONE(R) (glatiramer acetate injection) following brief immunosuppression with mitoxantrone experienced a 90 percent reduction in magnetic resonanc...

Annual Meeting of the Consortium of Multiple Sclerosis Centers Focuses on the Challenges of Care and Research in Multiple Sclerosis

WASHINGTON, June 01, 2007 /PRNewswire/ -- The annual meeting of the Consortium of Multiple Sclerosis Centers (CMSC), the largest meeting devoted to the comprehensive care and science of multiple sclerosis (MS), is underway in the nation's capital today. Multiple sclerosis, a disease of the central...

Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients With Relapsing Multiple Sclerosis

- Anti-IL-2 receptor antibody significantly reduced the number of new or enlarged lesions compared to placebo; data to be submitted for presentation at upcoming medical meeting - CAMBRIDGE, Mass. and FREMONT, Calif., March 12, 2007 /PRNewswire-FirstCall/ -- Biogen Idec, Inc. and PDL BioPharma, Inc...

Nutra Pharma Announces Publication of Research on Treatment for Multiple Sclerosis

BOCA RATON, Fla.--(BUSINESS WIRE)--Mar 22, 2007 - Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis has today announced that its drug discovery division, ReceptoPharm, has received notification of acceptance of its paper for publicatio...

Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with Tovaxin for Multiple Sclerosis

THE WOODLANDS, Texas--(BUSINESS WIRE)--Apr 3, 2007 - Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company involved in the development and commercialization of cell therapies, today announced positive top-line data in an open-label Phase I/II dose escalation clinical trial of the investigational T-cel...

New One-Year Pharmacoeconomic Study Shows Avonex is Cost-Effective Relative to Other Interferon Therapies for Multiple Sclerosis

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 13, 2007 - Biogen Idec Inc. (NASDAQ: BIIB) announced today that one-year data presented at the Academy of Managed Care Pharmacy's (AMCP) 2007 Annual Meeting show that AVONEX(R) (Interferon beta-1a) is a cost-effective therapy in multiple sclerosis (MS) when co...

Data Presented at the American Academy of Neurology's Annual Meeting Provide Update on Utilization and Safety of Tysabri in Patients with Multiple Sclerosis

BOSTON--(BUSINESS WIRE)--May 3, 2007 - Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced today that new data from the TOUCH Prescribing Program(TM) and TYGRIS safety study confirm the safety profile from previous clinical studies of TYSABRI(R) (natalizumab). Also presented ...

Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis

Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis Combination Treatment With Antibiotic Further Reduced Brain Lesions and Was Well Tolerated KANSAS CITY, Mo, May 4, 2007 - New data from a ran...

Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis

KANSAS CITY, Mo.--(BUSINESS WIRE)--May 4, 2007 - New data from a randomized, double-blind study showed that a combination of COPAXONE(R) (glatiramer acetate injection) along with the oral antibiotic minocycline reduced T1 Gadolinium (Gd)-enhancing lesions of the brain by 63 percent (p=0.08) in pati...

Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis

- New Data from Open-Label Study Presented at Federation of Clinical Immunology Societies (FOCIS) Annual Meeting - CARLSBAD, Calif., June 11, 2007 /PRNewswire-FirstCall/ -- Orchestra Therapeutics, Inc. (Bulletin Board: OCHT) announced today positive new data from its completed Phase II open-label ...

Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 21, 2007 - Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company involved in the development and commercialization of cell therapies, today announced positive top-line data in an open-label Phase I/II extension clinical trial of the investigational T-cell vacc...

Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting

...ous etiologies including stroke, brain injury, spinal cord injury, multiple sclerosis or cerebral palsy, warranting additional studies as a potential treatment o...imb spasticity caused by either stroke (88%), brain injury (5.7%), multiple sclerosis (0.5%) or cerebral palsy (1.6%) were randomized to the 50 U/mL dilution gro...

Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial

...ney cancer. Afinitor is being studied in multiple cancer types, including NET, breast, gastric and hepatocellular carcinoma (HCC), as well as tuberous sclerosis complex (TSC) and NHL. The active ingredient in Afinitor is everolimus, which is available in different dosage strengths under the trade name Ce...